Biopharma shares, which began the week on a agency footing, misplaced momentum mid-way via amid market-wide sell-off triggered by waning stimulus hopes.
The week was a quiet one from the attitude of reports stream. Johnson & Johnson (NYSE: JNJ) was within the information for each proper and flawed causes. The corporate’s Section three trial of its coronavirus vaccine was paused resulting from a trial participant contracting an unexplained sickness. On a constructive be aware, the corporate reported strong quarterly outcomes and lifted its steerage.
Medical trial disappointments led to Vertex Prescribed drugs Integrated (NASDAQ: VRTX) and Cyclerion Therapeutics Inc (NASDAQ: CYCN) shelving alpha-1 antitrypsin deficiency and sickle cell illness research, respectively.
The week witnessed Nasdaq debuts by six biopharma firms, which collectively raised about $650 million in gross proceeds.
Right here are the important thing catalysts for the unfolding week.
American Faculty of Chest Physicians’ CHEST Annual Assembly 2020, being held nearly: Oct. 18-21
The Prostate Most cancers Basis’s 27th Annual Scientific Retreat: Oct. 20-23
IDWeek 2020: Oct. 20-25
American Society of Nephrology, or ASN, Kidney Week 2020 Annual Assembly: Oct. 22-25 (early applications scheduled for Oct. 19-21)
32nd European Organisation for Analysis and Remedy of Most cancers-the Nationwide Most cancers Institute- the American Affiliation for Most cancers Analysis, or EORTC-NCI-AACR, Symposium: Oct. 24-25
Zosano Pharma Corp’s (NASDAQ: ZSAN) NDA for its migraine drug Qtrypta has a PDUFA motion date of Oct. 20. With the corporate disclosing in late September that it has acquired a self-discipline evaluation letter, which raised two issues concerning the scientific pharmacology part of the NDA, a call by the d-day appears unlikely.
The FDA is ready to rule on Spectrum Prescribed drugs, Inc.’s (NASDAQ: SPPI) BLA for SPI-2012 to deal with chemotherapy-induced neutropenia. The PDUFA date is Oct. 24.
Pfizer Inc. (NYSE: PFE) is scheduled to current on the ID Week 2020 full outcomes of the pediatric Section 2 proof-of-concept research of 20vPNC and detailed outcomes from a Section 2 proof-of-concept research of its potential first-in-class pentavalent meningococcal vaccine candidate.
Alnylam Prescribed drugs, Inc. (NASDAQ: ALNY) will current on the ASN assembly outcomes from the ILLUMINATE-B pediatric Section three research of lumasiran in treating major hyperoxaluria kind 1.
Omeros Company (NASDAQ: OMER) is because of current last outcomes of its pivotal trial of narsoplimab within the remedy of hematopoietic stem cell transplant-associated thrombotic microangiopathy. The presentation, within the type of a webcast, is scheduled for Oct. 22.
Mustang Bio Inc (NASDAQ: MBIO), based by Fortress Biotech (NASDAQ: FBIO), is scheduled to current on the Prostate Most cancers Basis’s annual scientific retreat preliminary Section 1 knowledge on CAR-T cell remedy MB-105 in sufferers with PSCA-positive metastatic castration-resistant prostate most cancers. The presentation is fastened for Oct. 23.
Associated Hyperlink: 9 Biotech Stocks With Material Catalysts In Q4
EORTC-NCI-AACR Symposium Displays
Cyclacel Prescribed drugs Inc (NASDAQ: CYCC): Section 1 security, pharmacokinetic and pharmacodynamic research of fadraciclib (CYC065), a cyclin dependent kinase inhibitor, in sufferers with superior most cancers (Oct. 24)
Revolution Medicines Inc (NASDAQ: RVMD): interim knowledge from the Section 1b/2 scientific trial evaluating the mix of RMC-4630 and cobimetinib in grownup sufferers with relapsed/refractory strong tumors that harbor particular genomic mutations. (Oct. 24)
Aileron Therapeutics Inc (NASDAQ: ALRN): proof-of-concept knowledge from the Section 1b research of ALRN-6924 as a therapeutic agent administered forward of chemotherapy to forestall chemotherapy-induced toxicities, comparable to extreme anemia, neutropenia and thrombocytopenia, in sufferers with p53-mutated small cell lung most cancers, who’re being handled with the chemotherapy topotecan (Oct. 24)
Turning Level Therapeutics Inc (NASDAQ: TPTX): First-in-human security, pharmacokinetics, and preliminary efficacy of TPX-0022 in sufferers with superior strong tumors harboring genetic alterations in MET (Oct. 24)
Syros Prescribed drugs Inc (NASDAQ: SYRS): preliminary knowledge from the continued dose escalation portion of its Section 1 scientific trial of SY-5609, its extremely selective and potent oral CDK7 inhibitor, in sufferers with choose strong tumors. (Oct. 24)
Abbott Laboratories (NYSE: ABT) (Wednesday, earlier than the market open)
Biogen Inc (NASDAQ: BIIB) (Wednesday, earlier than the market open)
Edwards Lifesciences Corp (NYSE: EW) (Wednesday, after the shut)
Quest Diagnostics Inc (NYSE: DGX) (Thursday, earlier than the market open)
Neurometrix Inc (NASDAQ: NURO) (Thursday, earlier than the market open)
West Pharmaceutical Companies Inc. (NYSE: WST) (Thursday, earlier than the market open)
Plus Therapeutics Inc (NASDAQ: PSTV) (Thursday, after the shut)
IPO Quiet Interval Expiry
Taysha Gene Therapies Inc (NASDAQ: TSHA)
Prelude Therapeutics Inc (NASDAQ: PRLD)
PMV Prescribed drugs Inc (NASDAQ: PMVP)
Orphazyme A S ADR (NASDAQ: ORPH)
See extra from Benzinga
© 2020 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.